Novo Nordisk’s Sogroya Approved for Adult Growth Hormone Deficiency
The FDA has approved Novo Nordisk’s Sogroya (sompacitan) for adults with growth hormone deficiency.
The approval was based on a phase 3 clinical trial, in which patients taking weekly Sogroya had truncal fat, which is regulated by growth hormone, decrease by 1.06 percent on average compared to it increasing by 0.47 percent among patients given a placebo at the end of a 34-week treatment period.
Sogroya is the first human growth hormone therapy that is only taken once a week by injection under the skin. Other approved therapies must be administered daily.